| Business Summary | | Pharmacyclics
Inc.
is
a
pharmaceutical
company
developing
products
to
improve
upon
current
therapeutic
approaches
to
the
treatment
of
cancer,
atherosclerosis
and
retinal
disease.
The
Company
uses
its
expertise
in
the
chemistry
of
biologically-active
metal-containing
compounds
to
develop
patented
molecules
called
texaphyrins
which,
when
injected,
accumulate
in
tumor
growths,
in
the
diseased
portions
of
major
blood
vessels
and
in
small
blood
vessel
growths
in
the
retina.
Its
lead
texaphyrin-based
product
candidates
are:
XCYTRIN,
a
molecule
to
enhance
the
effects
of
radiation
and
chemotherapy
in
treating
cancer;
LUTRIN,
a
molecule
for
use
in
photodynamic
therapy
of
cancer;
ANTRIN,
a
molecule
to
treat
atherosclerosis
via
photoangioplasty;
and
OPTRIN,
a
molecule
to
treat
age-related
macular
degeneration,
a
disease
of
the
retina
caused
by
growth
of
small
blood
vessels,
which
can
lead
to
blindness. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Pharmacyclics
Inc.,
develops
pharmaceutical
products
to
improve
upon
therapeutic
approaches
to
the
treatment
of
cancer,
atherosclerosis
and
retinal
disease.
For
the
nine
months
ended
3/31/01,
revenues
fell
71%
to
$409
thousand.
Net
loss
rose
39%
to
$22.7
million.
Revenues
reflect
a
decrease
in
contract
revenues
associated
with
the
development
of
LUTRIN.
Higher
loss
was
partially
offset
by
reduced
drug
purchase
costs. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
2,712;
after
tax
earnings
were
-8,194. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Richard Miller, M.D., 49 Pres,
CEO | $300K | Leiv Lea, 46 CFO,
VP of Fin. and Admin. | 181K | Cynthia Ladd, 45 Sr.
VP, Sec., Gen. Counsel | -- | Marc Steuer, 53 Sr.
VP of Bus. Devel. | 262K | Hugo Madden, Ph.D., 50 VP
of Chemical Operations | 174K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|